Micro Developing Active

I risultati contrastanti della sperimentazione del retatrutide di LLY

Punteggio
0,4
Velocità
▲ 1,0
Articoli
6
Fonti
2

Riepilogo

Un articolo appartiene a questa narrazione se discute i risultati misti del trial di retatrutide di Eli Lilly and Company (LLY) per il trattamento del diabete di tipo 2.

Articoli Correlati

Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster”

Yahoo Finance · Apr 05, 2026
Mixed

Should You Buy Eli Lilly Stock Before April 10?

Nasdaq · Mar 22, 2026
Mixed

Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial

Yahoo Finance · Mar 22, 2026
Bearish

RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results

Yahoo Finance · Mar 21, 2026
Mixed

Fonti

Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be … Yahoo Finance
1 Reason Eli Lilly Stock Is Still a Buy Nasdaq
Should You Buy Eli Lilly Stock Before April 10? Nasdaq
Eli Lilly and Company (LLY) Announces Positive Topline Results From … Yahoo Finance
RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth … Yahoo Finance

Cronologia

Ultimo aggiornamento Mar 21, 2026